Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash balance ...

Nkarta, Inc. (NKTX) has been beaten down lately with too much selling pressure. While the stock has lost 33.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

A downtrend has been apparent in Nkarta, Inc. (NKTX) lately with too much selling pressure. The stock has declined 32.6% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for s ...

Company Overview - Nkarta, Inc. is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases [2] - The company utilizes a combination of cell expansion, cryopreservation platforms, proprietary cell engineering technologies, and CRISPR-based genome engineering to create its therapies [2] Upcoming Events - Nkarta will participate in the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 3:10 p.m. ET for a fireside chat [1] - The company will also be present at the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 3:00 p.m. ET for another fireside chat [1] - Both events will be available via simultaneous webcast on Nkarta's website, with replays archived for approximately 90 days [1]

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis Patient dosing initiated and enrollment open in Ntrust-1 and IST of NKX019 in systemic lupus erythematosus Clinical data from Ntrust-1 and Ntrust-2 planned for 2025 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a b ...

Company Overview - Nkarta, Inc. is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies [2] - The company utilizes a combination of cell expansion, cryopreservation platforms, proprietary cell engineering technologies, and CRISPR-based genome engineering to advance its therapies [2] Upcoming Events - Nkarta will participate in the Stifel 2024 Healthcare Conference on November 19, 2024, at 10:55 a.m. ET, featuring a fireside chat [1] - A simultaneous webcast of the event will be available on Nkarta's website, with a replay archived for approximately 90 days [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4515206 (State or other jurisdiction of ...

Exhibit 99.1 Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights • First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies • Enrollment in Ntrust-2 expected to initiate by year-end 2024 • Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 • No further NKX019 development in lymphoma planned • Platform prioritized to focus on advancement of NKX019 for multiple autoimmune di ...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 26th Annual Global Investment Conference September 10, 2024 12:30 p.m. ET – fireside chat A simultaneous webcast of each event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the ...

One analyst is now more bullish about this clinical-stage biotech stock. Shares of Nkarta (NKTX 1.61%) were soaring 11.1% as of 11:07 a.m. ET on Wednesday. The big gain came after Raymond James upgraded the stock from outperform to a strong buy and maintained its 12-month price target at $16. This analyst upgrade came after Nkarta provided its second-quarter update on Tuesday. The clinical-stage biopharmaceutical company expects to begin patient enrollment by year-end in an Ntrust-2 clinical trial evaluatin ...